Livforsakringsbolaget Skandia Omsesidigt Buys 1,400 Shares of Revvity, Inc. (NYSE:RVTY)

Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 686.3% during the third quarter, HoldingsChannel reports. The fund owned 1,604 shares of the company’s stock after purchasing an additional 1,400 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Revvity were worth $205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Contravisory Investment Management Inc. purchased a new stake in Revvity during the third quarter valued at about $487,000. Steigerwald Gordon & Koch Inc. lifted its holdings in Revvity by 1.7% in the third quarter. Steigerwald Gordon & Koch Inc. now owns 114,483 shares of the company’s stock worth $14,625,000 after buying an additional 1,960 shares during the period. Atomi Financial Group Inc. purchased a new stake in Revvity in the third quarter worth about $218,000. GAMMA Investing LLC lifted its holdings in shares of Revvity by 35.4% during the third quarter. GAMMA Investing LLC now owns 1,713 shares of the company’s stock valued at $219,000 after purchasing an additional 448 shares during the last quarter. Finally, Czech National Bank increased its position in shares of Revvity by 6.9% during the third quarter. Czech National Bank now owns 25,125 shares of the company’s stock valued at $3,210,000 after acquiring an additional 1,612 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Insider Buying and Selling

In other Revvity news, insider Tajinder S. Vohra sold 2,153 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $122.09, for a total value of $262,859.77. Following the sale, the insider now directly owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the transaction, the insider now owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tajinder S. Vohra sold 2,154 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at $2,392,237.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,807 shares of company stock valued at $937,576 over the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Revvity Stock Up 1.2 %

RVTY opened at $122.91 on Tuesday. The business has a 50 day moving average of $121.42 and a 200-day moving average of $112.63. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $15.17 billion, a price-to-earnings ratio of 101.58, a P/E/G ratio of 3.35 and a beta of 1.05. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $128.15.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. During the same quarter in the prior year, the firm posted $1.21 earnings per share. The business’s quarterly revenue was down 2.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Revvity, Inc. will post 4.75 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.23%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Wall Street Analyst Weigh In

RVTY has been the topic of a number of analyst reports. Jefferies Financial Group lifted their target price on shares of Revvity from $115.00 to $125.00 and gave the company a “hold” rating in a research note on Monday, July 29th. JPMorgan Chase & Co. upped their price target on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. TD Cowen increased their target price on shares of Revvity from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Leerink Partners began coverage on shares of Revvity in a report on Monday, July 8th. They issued an “outperform” rating and a $125.00 price target for the company. Finally, Barclays raised their price target on shares of Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 30th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.53.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.